Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. by Kouri, Naomi et al.
UC San Diego
UC San Diego Previously Published Works
Title
Genome-wide association study of corticobasal degeneration identifies risk variants 
shared with progressive supranuclear palsy.
Permalink
https://escholarship.org/uc/item/10b9b78t
Journal
Nature communications, 6(1)
ISSN
2041-1723
Authors
Kouri, Naomi
Ross, Owen A
Dombroski, Beth
et al.
Publication Date
2015-06-16
DOI
10.1038/ncomms8247
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ARTICLE
Received 30 Oct 2014 | Accepted 17 Apr 2015 | Published 16 Jun 2015
Genome-wide association study of corticobasal
degeneration identifies risk variants shared with
progressive supranuclear palsy
Naomi Kouri1,*, Owen A. Ross1,*, Beth Dombroski2, Curtis S. Younkin1,3, Daniel J. Serie3, Alexandra Soto-Ortolaza1,
Matthew Baker1, Ni Cole A. Finch1, Hyejin Yoon1, Jungsu Kim1, Shinsuke Fujioka1, Catriona A. McLean4,
Bernardino Ghetti5, Salvatore Spina5, Laura B. Cantwell2, Martin R. Farlow6, Jordan Grafman7,8, Edward D. Huey9,
Mi Ryung Han2, Sherry Beecher2, Evan T. Geller2, Hans A. Kretzschmar10,z, Sigrun Roeber10, Marla Gearing11,
Jorge L. Juncos12, Jean Paul G. Vonsattel13, Vivianna M. Van Deerlin2, Murray Grossman14, Howard I. Hurtig14,
Rachel G. Gross14, Steven E. Arnold15, John Q. Trojanowski2, Virginia M. Lee2, Gregor K. Wenning16, Charles L. White17,
Gu¨nter U. Ho¨glinger18,19,20, Ulrich Mu¨ller21, Bernie Devlin22, Lawrence I. Golbe23, Julia Crook1,3, Joseph E. Parisi24,
Bradley F. Boeve25, Keith A. Josephs25, Zbigniew K. Wszolek26, Ryan J. Uitti26, Neill R. Graff-Radford26, Irene Litvan27,
Steven G. Younkin1, Li-San Wang2, Nilu¨fer Ertekin-Taner1,26, Rosa Rademakers1, Hakon Hakonarsen28,
Gerard D. Schellenberg2,* & Dennis W. Dickson1,*
Corticobasal degeneration (CBD) is a neurodegenerative disorder affecting movement and cog-
nition, definitively diagnosed only at autopsy. Here, we conduct a genome-wide association study
(GWAS) in CBD cases (n¼ 152) and 3,311 controls, and 67 CBD cases and 439 controls in a
replication stage. Associations with meta-analysis were 17q21 atMAPT (P¼ 1.42 10 12), 8p12 at
lnc-KIF13B-1, a long non-coding RNA (rs643472; P¼ 3.41 108), and 2p22 at SOS1 (rs963731;
P¼ 1.76 10 7). Testing for association of CBD with top progressive supranuclear palsy (PSP)
GWAS single-nucleotide polymorphisms (SNPs) identified associations at MOBP (3p22;
rs1768208; P¼ 2.07 10 7) and MAPT H1c (17q21; rs242557; P¼ 7.91 10 6). We previously
reported SNP/transcript level associations with rs8070723/MAPT, rs242557/MAPT, and
rs1768208/MOBP and herein identified association with rs963731/SOS1. We identify new CBD
susceptibility loci and show that CBD and PSP share a genetic risk factor other thanMAPTat 3p22
MOBP (myelin-associated oligodendrocyte basic protein).
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C
BD is a late-onset neurodegenerative disorder that can
only be diagnosed upon neuropathologic examination,
which has impeded the ability to conduct genome-wide
association studies (GWASs). Similar to progressive supra-
nuclear palsy (PSP), Alzheimer’s disease (AD), and chronic
traumatic encephalopathy, CBD is a tauopathy, having abnormal
aggregates of microtubule-associated protein tau in the brain1.
Neuropathologic diagnostic criteria for CBD are based on tau
immunohistochemistry, requiring tau inclusions in neurons and
glia, with tau astrocytic plaques, and extensive thread-like
pathology in both grey matter and white matter1.
First described in 1968 by Rebeiz and colleagues, three CBD
cases were identified to have a distinct movement disorder and
neuropathologic profile2. These patients presented with what is
now termed corticobasal syndrome (CBS) where patients can
exhibit levodopa-unresponsive parkinsonism, asymmetric
akinesia and rigidity, accompanied by ideomotor apraxia,
dystonia, and myoclonus. Patients who present with the
archetypal CBS, however, do not necessarily have CBD
pathology upon neuropathologic examination. Furthermore,
autopsy-confirmed CBD cases can often present with several
different clinical syndromes3, which are frequently associated
with other underlying neurodegenerative disorders such as
PSP, AD, and frontotemporal dementia4. This phenotypic
variability results in o50% of patients with CBS having CBD
at autopsy5–7.
There are few reported families affected with CBD or PSP8–10,
yet genetic association studies of PSP have repeatedly shown an
increased risk for individuals carrying the H1 MAPT haplotype
at chromosome 17q21 (refs 11–14). An association of CBD
with the H1 haplotype was first reported in a series of 18 cases
(16 corticobasal syndrome patients and two autopsy-confirmed
CBD cases)15 and subsequently confirmed in a larger autopsy
series of 57 cases16. Recently, the first PSP GWAS17 discovered
three non-MAPT susceptibility loci at STX6, EIF2AK3, and
MOBP, raising the possibility that additional non-MAPT genetic
risk factors or modifiers may also exist for CBD. Recognition of
the lack of specificity of the corticobasal syndrome for CBD has
promoted increasing interest among clinicians to have autopsy
confirmation of patients thought to have CBD. Brain banks
focusing on atypical parkinsonian disorders, such as that
supported by the Foundation for PSP|CBD and Related Brain
Diseases18, have facilitated accumulation of sufficient number of
CBD cases to make identification of genetic contributions more
feasible. Here, we report a two-stage GWAS in autopsy-proven
CBD cases (n¼ 152 discovery stage, n¼ 67 replication stage)
compared with controls (n¼ 3,311 discovery stage, n¼ 457
replication stage). The results confirm the association at MAPT
and identify a novel susceptibility locus at 8p12 associated with
CBD at the genome-wide significant level, as well as suggestive
associations at 2p22 and 3p22. Importantly, we show that CBD
and PSP share a genetic risk factor other than MAPT, at 3p22
MOBP. These findings highlight the genetic similarities and
differences between CBD and PSP and suggest that the two
disorders may, at least in part, share common disease processes.
Results
Discovery GWAS and replication. Genotype data from 152
autopsy-proven CBD cases and 3,311 controls (Table 1) were
previously generated as part of the PSP GWAS17. The National
Institute of Health Office of Rare Diseases Research criteria were
used for making a neuropathologic diagnosis of CBD1. Discovery
stage cases collected from multiple institutions (Supplementary
Table 1) were genotyped by the Center for Applied Genomics at
the Children’s Hospital of Philadelphia using Human 660W-
Quad Infinium BeadChips, and control samples were genotyped
using the Illumina Human HapMap550 Infinium BeadChip.
Replication stage samples included 67 autopsy-proven CBD cases
(Mayo Clinic Florida Brain Bank, 6 CBD cases that failed quality
control and 61 new CBD cases collected since the GWAS
genotyping was performed) and 457 control individuals (mean
age at blood draw¼ 74 years) collected from Mayo Clinic Florida,
all of which were clinically diagnosed as being free of any
neurological disorder. For the replication stage, genotyping was
performed on the 67 CBD cases using Taqman genotyping assays
or Sanger sequencing and 30 CBD cases from the discovery stage
as an internal genotyping control.
These data were subjected to accepted GWAS quality control
measures. Individual samples were excluded with a genotype
failure rate 42%, cryptic relatedness or duplicate samples based
on identity by state. Genetic outliers were excluded on the basis of
distance to the nearest-neighbour approach, and population
substructure was assessed using multidimensional scaling (MDS)
analysis with PLINK19 (http://pngu.mgh.harvard.edu/Bpurcell/
plink/; Supplementary Fig. 1). Quantile–quantile (QQ) plots and
the genomic inflation factor (l) show that the first principal
component as a covariate in logistic regression analyses was
sufficient to correct for population substructure based on a
reduction of l from the unadjusted (l¼ 1.06) to adjusted
(l¼ 1.01; Supplementary Fig. 2).
For the discovery stage, we analysed association between
disease and 533,898 single-nucleotide polymorphisms (SNPs) in
152 CBD cases and 3,311 control individuals by conditional
logistic regression under an additive model using the first MDS
principle component as a covariate using PLINK19. Given the
neuropathologic, clinical, and genetic overlaps between CBD and
PSP, we selected the top PSP GWAS SNPs at MAPT (the H1c
subhaplotype-tagging SNP, rs242557), MOBP, EIF2AK3, and
STX6 to test for association with CBD. The discovery stage
identified one genome-wide significant association at 17q21.31,
Table 1 | Description of samples.
Female Age onset/blood draw Age at death Disease duration
Cohort Total % n* Mean age Range (s.d.) n Mean age Range (s.d.) n Mean durationw Range (s.d.) n
Discovery stagez
CBD cases 152 50 150 64 33–80 (8.6) 103 70 44–91 (9.2) 144 6 2–14 (2.4) 103
Replication stage
CBD cases 67 48 67 64 40–83 (7.9) 67 70 54–96 (7.8) 67 6 2–14 (2.5) 61
Controls 457 54 457 74 24–97 (13.1) 457 — — — — — —
*n is the number of samples with available data. Values of n for each type of analysis do not add up to the total samples used because of missing values.
wDuration in years.
zControls (n¼ 3,311) were young healthy subjects recruited from the Children’s Hospital of Philadelphia Health Care Network (see Online Methods for details).
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which encompasses MAPT (rs393152, odds ratio (OR)¼ 3.45,
P¼ 6.71 10 9) testing using conditional logistic regression
analysis (Fig. 1a; Table 2) and 12 SNPs in LD with rs393152
(Supplementary Table 2). QQ plots including and excluding SNPs
at 17q21 show that the P value distribution is consistent with the
null, except for departures in the extreme tail (Supplementary
Fig. 3). We also found nominal evidence for association testing
using conditional logistic regression analysis at two novel
susceptibility loci—rs643472 (OR¼ 1.88, P¼ 7.12 10 7), an
intronic SNP in lnc-KIF13B-1 (TCONS_00014956, a large
intergenic non-coding RNA, or lincRNA) located between
KIF13B and DUSP4 on chromosome 8p12, and rs963731
(OR¼ 2.46, P¼ 2.04 10 6), an intronic SNP in SOS1 on
chromosome 2q22 (Supplementary Fig. 4). Testing for association
using conditional logistic regression analysis with the top PSP
GWAS SNPs identified rs1768208 (OR¼ 1.65, P¼ 3.86 10 5),
an intronic SNP in MOBP (myelin-associated oligodendrocyte
basic protein), and rs242557 (OR¼ 1.48, P¼ 1.20 10 3) at the
MAPT locus to be associated with CBD. The top SNP at EIF2AK3
(rs7571971) did not show an association with CBD (P¼ 0.057;
OR¼ 1.27), but the OR was of similar effect size as observed for
PSP (Supplementary Table 3).
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Figure 1 | Regional association plots. (a–d) Top loci associated with CBD compared with controls in the Discovery Stage (152 CBD, 3,311 controls) and the
Replication Stage (67 CBD, 457 controls). The most significant association is at 17q21, tagging the 1.2Mb inversion containingMAPT (a). New susceptibility
loci for CBD are located at 8p12 (b), 3p22 (c) and 2p22 (d). Genetic association testing was performed using conditional logistic regression analysis under
an additive model and corrected for population substructure using the first principal component from multidimensional scaling analysis (MDS) as a
covariate (l¼ 1.01). The y axis is  log10 P values and x axis is the genomic location of each SNP (circles) genotyped and imputed. Linkage disequilibrium
coefficients were derived from hg19 (1,000 Genomes March 2012, European population) and local estimates of recombination rates are from HapMap
samples (2008–03_rel22_B36; http://hapmap.ncbi.nlm.nih.gov). The random effects meta-analysis top SNP at each locus (purple diamonds).
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In an independent cohort of 67 autopsy-proven CBD cases
from the Mayo Clinic Florida Brain Bank and 457 control
individuals, a replication stage was performed for a total of seven
SNPs: the top five SNPs from the discovery stage (Po10 5) and
two PSP GWAS SNPs that showed nominally significant
association with CBD (rs1768208 and rs242557) (Table 2).
Association testing for these seven SNPs was performed using
conditional logistic regression under an additive model with age
and sex as covariates. Using PLINK to perform random effects
meta-analysis, or the weighted average of the effect sizes of the
discovery and replication stages, showed genome-wide significant
associations at MAPT (rs393152, Pmeta¼ 1.4 10 12) (Fig. 1a)
and lnc-KIF13B-1 (rs643472, Pmeta¼ 3.4 10 8; Table 2)
(Fig. 1b). SNPs at MOBP (rs1768208, Pmeta¼ 2.1 10 7)
(Fig. 1c), SOS1 (rs963731, Pmeta¼ 1.8 10 7) (Fig. 1d) and
MAPT H1c haplotype (rs242557, Pmeta¼ 7.9 10 6) had
suggestive evidence for association with CBD. Performing the
same random effects meta-analysis while including the number of
H1 alleles as a covariate, the association was lost (rs242557,
OR¼ 1.18, Pmeta¼ 0.11). The MAFs for the top SNPs in younger
controls of this study did not differ significantly from those of
older controls (N¼ 3,720) in three data sets from the National
Institute of Health Database for Genotypes and Phenotypes
(dbGaP; http://www.ncbi.nlm.nih.gov/gap; Supplementary
Table 4). Furthermore, we repeated the discovery stage CBD
GWAS with a different control data set, 1,986 controls from
dbGaP data set NeuroGenetics Research Consortium (NGRC-PD;
phs000196.v2.p1), analysed by logistic regression under an
additive model and found similar association results
(Supplementary Table 5).
Genotype imputation was performed to increase the resolution
of the top susceptibility loci. CBD cases and controls were imputed
to samples from the 1,000 Genomes Project (May 2011, European
reference population)20. Phasing was performed with SHAPEIT
v2.r790 (ref. 21; https://mathgen.stats.ox.ac.uk/genetics_software/
shapeit/shapeit.html) and genotype imputation was performed
with IMPUTE2 v2.3.1 (ref. 22; https://mathgen.stats.ox.ac.uk/
impute/impute_v2.html). Genomic coordinates for imputation
were selected at the most significant SNPs and their surrounding
gene(s). Testing for association of CBD with imputed genotypes
did not improve association results.
Top susceptibility loci were further examined with HaploRegv2
(http://www.broadinstitute.org/mammals/haploreg/documenta-
tion_v2.html), a tool for chromatin profiling, which allows one to
explore the impact of non-coding variants, such as those
identified in GWASs, by using in silico analysis coupled with
experiments to validate biochemical and functional activators
and repressors23,24. Results show that rs643472 is located in
an enhancer region in multiple cell lines and alters three
transcription factor motifs, rs963731 at 2p22 alters 18
regulatory motifs, and rs1768208 at 3p22 is in high LD
(R2¼ 0.89–0.98) with five SNPs that are located in enhancer
regions in several brain regions (Supplementary Table 6 and
Supplementary Fig. 5). Two of the five SNPs (rs631312 and
rs1768190) were further genotyped in CBD (n¼ 133) and
controls (n¼ 457), and association testing showed similar
results with CBD (OR¼ 1.89 (CI¼ 1.30–2.75), P¼ 8.77 10 4;
OR¼ 1.91 (CI¼ 1.31–2.77), P¼ 7.24 10 4, respectively) to
rs1768208 (Table 3).
Expression quantitative trait locus analysis. To further explore
potential biological mechanisms, RNA expression quantitative
trait loci (eQTL) analysis for the CBD risk loci were interrogated
in our expression GWAS (eGWAS)25 of B400 samples from
cerebellum and temporal cortex from neurodegenerative
disorders (Supplementary Table 7) using the Illumina Whole-
Genome DASL assay. Expression changes are a possible
mechanism of disease-associated functional variants, but other
mechanisms also need to be investigated in future studies. The
eGWAS data were queried for the top SNPs associated with CBD
(rs393152, rs963731, rs1768208, and rs242557). The eGWAS
Table 2 | Results from discovery stage, replication stage and meta-analysis.
MAF
SNP Chr Gene(s) Stage* Cases Controls OR (95% CI) P
rs393152w 17q21 MAPT Discovery 0.079 0.24 3.45 (2.29–5.34) 6.71 109
(H1/H2) Replication 0.068 0.24 4.37 (2.16–8.83) 4.12 10 5
Meta-analysis 3.70 1.42 10 12
rs643472 8p12 lnc-KIF13B-1 Discovery 0.35 0.23 1.88 (1.46–2.40) 7.12 10 7
Replication 0.32 0.22 1.67 (1.11–2.52) 0.014
Meta-analysis 1.82 3.41 108
rs963731 2p22 SOS1 Discovery 0.12 0.054 2.46 (1.70–3.57) 2.04 106
Replication 0.09 0.049 2.21 (1.09–4.50) 0.029
Meta-analysis 2.41 1.76 10 7
rs1768208 3p22 MOBP Discovery 0.39 0.29 1.65 (1.30–2.09) 3.86 10 5
Replication 0.39 0.25 1.89 (1.28–2.77) 1.30 10 3
Meta-analysis 1.71 2.07 10 7
rs242557 17q21 MAPT Discovery 0.45 0.35 1.48 (1.17–1.88) 1.50 10 3
(H1c) Replication 0.48 0.36 1.77 (1.25–2.52) 1.50 10 3
Meta-analysis 1.57 7.91 106
rs1860743 7q36 PRKAG2 Discovery 0.20 0.11 2.05 (1.52–2.78) 3.46 10 6
Replication 0.09 0.13 0.71 (0.39–1.31) 0.27
Meta-analysis 1.25 0.67
rs875125 21q22 TSPEAR Discovery 0.17 0.10 2.02 (1.48–2.75) 7.92 10 6
Replication 0.05 0.08 0.65 (0.29–1.46) 0.29
Meta-analysis 1.22 0.73
*Discovery stage (152 CBD, 3,311 controls); Replication stage (67 CBD, 457 controls). The discovery and replication stages were analysed by logistic regression under an additive model. The discovery
stage analysis was adjusted for the first multidimensional scaling principle component, and the replication stage was adjusted for age and sex.
wThe OR for rs393152 is referencing the risk associated with the major allele (MAPT H1 haplotype). The protective allele (MAPT H2 haplotype) has an OR (95% CI) of 0.29 (0.19–0.44) in the discovery
stage and 0.23 (0.11–0.46) in the replication stage. Genome-wide significantceis defined as variants associated with Po5 108. Chr, chromosome; CI, confidence interval; lnc, long non-coding (RNA);
MAF, minor allele frequency; OR, odds ratio.
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genotypes did not contain rs643472 (KIF13B/DUSP4 locus) or
any SNPs in LD at R240.5 with rs643472; and the call rates
for the two DUSP4 expression probes did not pass quality
control, precluding eQTL analysis with DUSP4 expression. SNPs
were tested for association with transcript levels in the eGWAS
cohort by multivariable linear regression using an additive
model, with the minor allele dosage (0, 1 or 2) as the
independent variable, and APOE e4 dosage (0, 1 or 2),
age at death, gender, PCR plate, RIN, and RIN-RINmean as
biological and technical covariates. The sample set was analysed
as a single cohort for maximum statistical power to detect
associations, while including a covariate for AD diagnosis.
As we previously reported25, there were significant SNP/
transcript associations with MAPT/rs8070723 (cerebellum:
P¼ 7.02 10 69; temporal cortex: P¼ 8.61 10 44) and
MOBP/rs1768208 (cerebellum: P¼ 1.71 10 7; temporal
cortex: 1.57 10 6). We also detected significant associations
with SOS1/rs963731 (cerebellum: P¼ 4.61 10 4; temporal
cortex: P¼ 2.80 10 6) upon eQTL analysis (Table 4).
Beta values for SNP/transcript associations showed increased
expression levels with each copy of the risk allele.
To determine whether the novel genome-wide significant
association at 8p12 (rs643472, an intronic SNP in lnc-KIF13B-1)
genotype correlates with differential expression levels, we
measured lnc-KIF13B-1 expression in RNA from superior frontal
cortex of 22 CBD and 20 normal cases using the mirVana Paris
RNA isolation kit and quantitative PCR (qPCR) by SYBR Green.
All qPCR reactions were technically replicated. Two different
qPCR assays targeting TCONS_00014956 were designed, one
targeting exon 1 (primer set A) and the other for exon 2 (primer
set B), which showed good correlation upon comparison of
expression levels using the two different primer sets (R2¼ 0.97).
This identified a statistical trend for greater lnc-KIF13B-1
expression with the minor risk allele (Supplementary Fig. 6).
Discussion
This first CBD GWAS on 152 autopsy-proven CBD patients and
3,311 control individuals has a clear limitation in terms of sample
size. Given that CBD is a rare disorder and that it can only be
diagnosed upon neuropathologic examination, this was the
largest possible cohort at the time of genotyping. To control the
false-positive rate due to the small sample size, a stringent
significance threshold (Po10 5) was applied in the discovery
stage to select SNPs for genotyping in the replication stage. This
proved to be a useful approach because the random effects meta-
analysis identified two associations that did not replicate
(Table 2). The disadvantage of applying stringent criteria is the
possibility of false-negative associations, as evidenced from the
power analysis, which show low power to detect genome-wide
associations of variants with modest effect sizes (Supplementary
Tables 8 and 9).
Both CBD and PSP now have confirmed genome-wide
significant associations at the MAPT locus. In addition, CBD
was also associated with rs242557 (P¼ 7.91 10 6), a SNP
tagging the H1c subhaplotype at 17q21, shown to be associated
with PSP and located in a regulatory region influencing MAPT
expression26. In support of the MOBP locus being a shared
genetic risk factor between CBD and PSP, CBD cases have an
even greater OR estimate compared with PSP (MAFCBD¼ 0.40;
OR¼ 1.71; MAFPSP¼ 0.36; OR¼ 1.39; ref. 17). Importantly, this
is the first non-MAPT genetic risk factor shared between CBD
and PSP. Yamamoto et al.27 described MOBP as one of the most
abundant oligodendrocyte-expressing proteins, similar to myelin
basic protein, with the main difference being that MOBP is only
expressed in myelin of the central nervous system. The results of
the current study and those of the PSP GWAS indicate an overlap
in genetic risk factors for PSP and CBD, but it appears that there
is additional genetic variation that differs between the two
disorders. Additional analyses of the novel susceptibility loci at
Table 3 | Association with Mayo CBD cohort and SNPs at MOBP predicted to be in regulatory enhancer regions.
SNP Gene CBD MAF Control MAF LD R2 rs1768208* OR (95% CI) P
rs631312 MOBP (Upstream) 0.39 0.25 0.84 1.89 (1.30–2.75) 8.77 104
rs1768190 MOBP (Intron 1) 0.40 0.26 0.78 1.91 (1.31–2.77) 7.24 104
rs1768208 MOBP (Intron 2) 0.40 0.29 — 1.89 (1.28–2.77) 1.27 10 3
Mayo CBD cohort is composed of 133 autopsy-proven CBD cases and were tested for association with 457 controls from the replication stage. Association testing was performed using logistic regression
under an additive model, with age and sex as covariates.
*Linkage disequilibrium (LD) values from HapMap release 27 with top MOBP SNP associated with CBD, rs1768208 (Meta-analysis results, OR¼ 1.71, Pmeta¼ 2.07 10 7).
Table 4 | CBD GWAS SNP/transcript associations in cerebellar and temporal cortex human tissue samples.
Cerebellum Temporal cortex
SNP Chr Gene Probe Beta P Beta P
rs963731 2 SOS1 ILMN_1767135 0.154 4.61 104 0.178 2.80 10 6
rs1768208 3 MOBP ILMN_2298464 0.363 1.71 10 7 0.325 1.57 106
rs1768208 3 MOBP ILMN_2414962 0.243 1.17 104 0.180 1.76 10 5
rs1768208 3 MOBP ILMN_1768947 0.143 7.57 10 3 0.107 3.03 10 3
rs1768208 3 MOBP ILMN_1750271 0.074 0.021 0.046 0.016
rs242557 17 MAPT ILMN_1710903 0.183 8.80 10 13 0.181 1.10 10 8
rs242557 17 MAPT ILMN_2298727 0.071 9.78 10 3 0.041 0.11
rs242557 17 MAPT ILMN_2310814 0.002 0.83 0.026 0.22
rs8070723 17 MAPT ILMN_1710903 0.473 7.02 1069 0.498 8.61 1044
rs8070723 17 MAPT ILMN_2298727 0.173 3.36 10 7 0.137 9.03 104
rs8070723 17 MAPT ILMN_2310814 0.007 0.58 0.018 0.37
Top CBD GWAS SNPs were tested for transcript associations in 374 human cerebellum and 399 temporal cortex samples. Linear regression was employed using an additive model, with the minor allele
dosage (0, 1, 2) as the independent variable, and APOE e4 dosage (0, 1, 2), age at death, gender, PCR plate, RIN, (RIN-RINmean) as biological and technical covariates14.
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chromosomes 8p12 and 2p22 have the potential to advance our
understanding of CBD. The chromosome 8p12 locus contains
three candidate genes—lnc-KIF13B-1 (TCONS_00014956, a large
intergenic non-coding RNA or lincRNA); kinesin family member
13B (KIF13B); and dual-specificity protein phosphatase 4
(DUSP4), also known as MAP kinase phosphatase-2 (MKP-2)).
Although the lnc-KIF13B-1 expression levels were not
significantly different between CBD and normals, there was a
trend for greater expression with the minor risk allele. KIF13B is a
plus end-directed microtubule motor protein highly expressed
in the brain, and is involved in synaptic vesicle trafficking
along microtubules, neurite extension, and caveolin-dependent
endocytosis28–30. Of interest is that one of the PSP risk variants is
in the gene STX6 and is a SNARE-class protein that regulates
vesicle membrane fusion, which raises the possibility that
dysfunction of vesicular trafficking may be a common disease
mechanism between CBD and PSP.
DUSP4 acts through tyrosine and threonine-directed depho-
sphorylation31. Because tau phosphorylation plays a critical role
in tauopathies32, it will be interesting if DUSP4 is responsible for
the genetic association at 8p12. Indeed, in Alzheimer’s disease
brain tissue there is decreased enzymatic activity of tau
phosphatases such as PP-2A and PP-1 (ref. 33), indicating that
a potential role for variants in DUSP4 in CBD pathogenesis would
be through aberrant tau phosphorylation. Furthermore, the
chromosome 2p22 locus contains son of sevenless homologue 1
(SOS1), a guanine nucleotide exchange factor for Ras that has a
catalytic region known as the cdc25 domain due to sequence
homology to CDC25, a dual-specificity phosphatase34. Taken
together, the novel susceptibility loci for CBD may link common
genetic variation to aberrant tau phosphorylation.
In conclusion, this first CBD GWAS identified MAPT and
MOBP as shared genetic risk factors between CBD and PSP.
Given the significant white matter and oligodendrocyte pathology
in these primary tauopathies, the genetic association with MOBP
warrants functional characterization to determine its role in CBD
and PSP.
Methods
Samples. The discovery stage cohort was comprised of 152 autopsy-proven CBD
cases collected from eight institutions (Table 1 and Supplementary Table 1).
Discovery stage controls were recruited from the Children’s Hospital of Philadel-
phia Health Care Network, and although these controls are not age matched to the
cases, the justification for using this cohort is that they were all genotyped at the
same center using the same protocol as the CBD cases. Furthermore, because CBD
is such a rare disorder with an estimated prevalence of 4.9–7.3 cases per 100,000
individuals35, the chance of any of the young controls developing CBD at a later
age is negligible. As described in the PSP GWAS17, to ensure significant
associations were not confounded by using young controls, allele frequencies for
the top associated SNPs were compared and found to be similar to older controls
(N¼ 3,720) from three data sets downloaded from the National Institute of Health
(NIH) Database for Genotypes and Phenotypes (dbGaP).
DNA was extracted from the brain tissue of CBD patients and from the blood
samples of controls. Brain autopsies were obtained after consent of the legal next-
of-kin and are considered exempt from human subject research. Written informed
consent was obtained from control individuals as approved by The Institutional
Review Board (University of Pennsylvania) and Mayo Clinic Institutional Review
Board.
Power analyses were estimated for the Discovery Stage and Replication Stage for
various minor allele frequencies and odds ratios with 1,000 simulations of each
scenario (Supplementary Tables 8 and 9). The power assessment assumes that
genotype frequencies are in Hardy–Weinberg equilibrium in CBD cases and
control individuals separately and that association testing is performed using
logistic regression under an additive model.
Quality control. Quality control of genotyping data was performed at the
individual level and then at the SNP level. For quality control, 10 individuals were
genotyped in duplicate. Exclusion criteria for individual samples included high
genotype failure rate (six individuals were removed because of a genotype failure
rate 42%) and cryptic relatedness. Genetic outliers were excluded from further
analyses on the basis of identity by state and distance to the nearest-neighbour
analysis was conducted in PLINK19 (five CBD cases and 341 controls were
removed on the basis of Z-score distributions for the first to the fifth neighbour,
Z-scoreo 2). Gender inconsistencies were assessed by chromosome X genotypes,
which excluded six individuals on the basis of observed and expected gender.
Exclusion criteria for markers included minor allele frequency (24,183 SNPs were
removed because of minor allele frequency o1%), deviation from Hardy–
Weinberg equilibrium in controls (1,098 SNPs gave a Hardy–Weinberg
expectations test, P value r10 7), and high genotype failure rates (3,199 SNPs
were removed because of genotype failure rates 42%).
Population substructure. MDS was applied to a pruned data set (B140,000
markers) using PLINK. Scatter plots for the first two principle components were
generated using R (Supplementary Fig. 1a). Analysis of population stratification
showed that the first principle component was sufficient to reduce the genomic
inflation factor (l) from 1.06 to 1.01, as illustrated by the quantile–quantile (QQ)
plots of observed versus expected P values. Using the first two principal compo-
nents resulted in l¼ 1.02 (Supplementary Fig. 2b); thus, only the first MDS
principal component was used as a covariate for all subsequent analyses.
Association analysis. CBD versus control association was tested by conditional
logistic regression under an additive model using the first MDS principle
component as a covariate. We also tested for association from a subset of samples
from stage 1, excluding outliers based on population substructure (Supplementary
Fig. 1b), which yielded similar results. For rs242557, additional association testing
was performed, conditioning on MAPT haplotype (that is, using 0, 1 or 2 as a
covariate for the number of H1 alleles per individual). Linkage disequilibrium
values were derived from HapMap 3 release 27.
CBD cases and controls were imputed up to the 1000 Genomes European
reference20, May 2011 release (phase 1, version 3; hg19). SHAPEIT v2.r790 (ref. 21)
was used for phasing and IMPUTE2 v2.3.1 (ref. 22) was used for genotype
imputation. Imputed variants with MAF o0.01 or dosage R2o0.3 were excluded,
and all downstream analyses were based on the most likely genotype36. Regional
genome-wide association plots were created with LocusZoom37 (http://csg.sph.
umich.edu/locuszoom/). HaploRegv2 (Broad Institute) uses linkage disequilibrium
information from 1000 Genomes Project, SNPs (based on dbSNP 137), motif
instances (based on PWMs discovered from ENCODE experiments), and
enhancer annotations (adding 90 cell types from the Roadmap Epigenome
Mapping Consortium)23,24.
eQTL analysis. These data were generated and previously reported in a brain
expression GWAS (eGWAS) by Zou et al.25, where the detailed mRNA extraction
and quality assessment using RNAqueous kit (Ambion, Grand Island, NY) and
RNA 6,000 Nano Chip (Agilent, Santa Clara, CA), Whole Genome DASL assay
(Illumina, San Diego, CA), and data quality control methods can be found. This
eGWAS cohort included 374 cerebellar and 399 temporal cortex mRNA samples
from the Mayo Clinic Florida Brain Bank. Neuropathologic diagnoses for the
cohort include Alzheimer’s disease, PSP, CBD, Lewy body disease, frontotemporal
lobar degeneration, and other diagnoses (Supplementary Table 7). The Bonferroni
P value threshold for SNP/transcript association significance was Po1.56 10 3
(four SNPs and eight probes).
RNA preparation for lnc-KIF13B-1 expression studies. Superior frontal cortex
tissue was isolated from CBD cases and normal controls from the Mayo Clinic
Florida brain bank and matched for age at death and gender. Total RNA from brain
tissue samples was extracted with acid–phenol: chloroform chemistry using mir-
Vana PARIS isolation kit (Ambion). Total RNA concentration was determined with
a NanoDrop ND-1,000 spectrophotometer (NanoDrop, Wilmington, DE). RNA
quality control was performed using a 2,100 Bioanalyzer (Agilent, Santa Clara, CA)
to measure RNA integrity number (RIN) and only samples with an RNA integrity
value45 were included in this study. The mean RIN in frontal cortex for 22 CBD
cases (5.6±0.38) were not different from 19 controls (6.4±0.77).
Real-time quantitative PCR for lincRNA. Five hundred nanograms of total RNA
from the human superior frontal of CBD patients (n¼ 22) and normal controls
(n¼ 19) were reverse transcribed with High Capacity cDNA Reverse Transcription
kit (Applied Biosystems, Carlsbad, CA). Quantitative PCR (qPCR) was performed
using Fast SYBR Green PCR Master Mix (Applied Biosystems) and StepOnePlus
(Applied Biosystems) according to the company’s suggested protocol and thermal
cycling programme. A final dissociation step was performed at the end of the qPCR
assay to evaluate the specificity of amplification. All qPCR reactions were technically
replicated. Two different qPCR assays targeting TCONS_00014956 were designed,
one targeting exon 1 (Primer set A) and the other for exon 2 (Primer set B). All the
primers were purchased from Sigma Life Science (Sigma, St Louis, MO) with the
sequences shown in Supplementary Fig. 6. The relative levels of lincRNA were
calculated by comparative Ct method using StepOne Software v2.3 (Applied Bio-
systems, Grand Island, NY) and GeneEx 5.3.2 (Multid Analyses, Go¨teborg, Sweden).
GAPDH was used as a normalization control. Statistical analysis was performed
using GraphPadPrism v5.04 (GraphPad, La Jolla, CA).
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